Florida Clinical Research Center (FCRC) was founded in 1998 by Dr. Andrew Cutler and specializes in research for psychiatric and other central nervous system (CNS) disorders like ADHD, Alzheimer’s dementia, anxiety, bipolar disorder, depression, schizophrenia, insomnia, migraine headache and other pain disorders.
Meridien Research opened their doors in 2000 in St. Petersburg and currently has five clinics throughout the Tampa Bay area (Brooksville, Lakeland, Tampa, St. Petersburg and Bradenton). Meridien acquired FCRC’s Bradenton location earlier this year. In July, the two clinics combined at the FCRC location in Bradenton to become the largest stand-alone clinical research site in Manatee and Sarasota counties and surrounding areas. The combination of the two sites expands the types of studies offered to include psychiatric, CNS and general medical clinical trials.
Meridien Research President and CEO, Anthony ‘Tony’ Busa, Jr. is excited about expanding into Maitland. “There are three primary reasons; Orlando is on the I-4 corridor, it is the 5th largest city in Florida and is located at the northern most perimeter of the Meridien strategic growth plan. Hence with the inclusion of Orlando, Meridien is now located in three of the five largest cities in Florida – Orlando (5th), Tampa (3rd) and St. Petersburg (4th),” he explained. “Meridien’s strategic growth plan looks to expand further to the southwest towards Naples and Ft. Myers.”
The acquisition of the two FCRC sites makes Meridien Research the largest wholly-owned stand-alone clinical research organization in central Florida offering medical research studies in more than 60 different therapeutic areas.
The majority of the FCRC management team will remain in their current positions. Dr. Andrew Cutler, current CEO and Chief Medical Officer (CMO) of FCRC, will become Meridien’s Executive Vice President and CMO.
“Meridien Research has never had a Chief Medical Officer and we will benefit greatly from his clinical research experience and expertise as a highly recognized Principal Investigator in many pivotal drug development programs,” Busa explained. “Meridien will not only enjoy the enhanced visibility and market recognition, but will gain greater efficiencies, systems, and procedural applications with his active involvement with the combined medical and clinical staff.”
“I am happy to join our organization with a high-quality company such as Meridien Research with an outstanding reputation for integrity and quality,” notes Dr. Cutler. “Our two companies are very complementary in culture and mission, and this is a good fit for us both. I am proud to become EVP and CMO of Meridien Research, and being board certified in both Psychiatry and Internal Medicine, I am thrilled with the expanded capacity to perform studies in a broader range of therapeutic areas this acquisition affords. It will also enable us to offer studies of even greater technical sophistication and relevance to the people of Florida that we serve and to our customers in the pharmaceutical and biotechnology industries.”
For more information about the merger between Meridien Research and FCRC, please call 888-777-8839.